ZVRA insider transaction filings
ZEVRA THERAPEUTICS, INC. — 49 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-17. Screen ZVRA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-17 | 4 | Thompson Rahsaan — Chief Legal & Compliance | Sale (S): 42,666 @ $11.13 | EDGAR |
| 2026-08-12 | 4 | Watton Corey Michael — Director | Option exercise (M): 12,300 @ $4.97 · Sale (S): 12,300 @ $11.25 · Option exercise (M): 12,300 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Thompson Rahsaan — Chief Legal & Compliance | Option exercise (M): 66,667 · Sale (S): 34,557 @ $12.68 · Option exercise (M): 66,667 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Secor Alicia — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Watton Corey Michael — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Calder Douglas W — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Anderson Thomas — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Shih Alvin — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | FAVORITO TAMARA A — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Sangiovanni Timothy J. — SVP, Finance & Corp Controller | Grant/award (A): 40,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Thompson Rahsaan — Chief Legal & Compliance | Sale (S): 1,794 @ $11.30 | EDGAR |
| 2026-03-26 | 4 | Bode John B — Director | Option exercise (M): 39,200 @ $4.97 · Option exercise (M): 39,200 @ $4.89 · Option exercise (M): 39,200 (derivative) @ $0 · Option exercise (M): 39,200 (derivative) @ $0 | EDGAR |
| 2026-03-19 | 4 | Renz Justin A — CFO | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | McFarlane Neil F. — President and CEO, Director | Option exercise (M): 37,500 · Sale (S): 14,625 @ $8.56 · Option exercise (M): 37,500 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Schafer Joshua — CCO | Sale (S): 10,500 @ $9.19 | EDGAR |
| 2026-02-04 | 4 | Sangiovanni Timothy J. — SVP, Finance & Corp Controller | Sale (S): 3,000 @ $9.18 | EDGAR |
| 2026-02-02 | 4 | Schafer Joshua — CCO | Option exercise (M): 11,333 · Sale (S): 3,375 @ $8.83 · Option exercise (M): 35,334 · Grant/award (A): 37,500 (derivative) @ $0 · Grant/award (A): 75,000 (derivative) @ $0 · Option exercise (M): 11,333 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-02 | 4 | Quartel Adrian W — Chief Medical Officer | Option exercise (M): 11,333 · Sale (S): 4,533 @ $8.83 · Grant/award (A): 37,500 (derivative) @ $0 · Grant/award (A): 75,000 (derivative) @ $0 · Option exercise (M): 11,333 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Thompson Rahsaan — Chief Legal & Compliance | Option exercise (M): 11,333 · Sale (S): 4,080 @ $8.83 · Grant/award (A): 37,500 (derivative) @ $0 · Grant/award (A): 75,000 (derivative) @ $0 · Option exercise (M): 11,333 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Sangiovanni Timothy J. — SVP, Finance & Corp Controller | Option exercise (M): 6,333 · Sale (S): 1,750 @ $8.82 · Option exercise (M): 11,666 · Option exercise (M): 6,333 (derivative) @ $0 · Option exercise (M): 11,666 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | McFarlane Neil F. — President and CEO, Director | Option exercise (M): 233,334 · Sale (S): 91,000 @ $9.38 · Grant/award (A): 125,000 (derivative) @ $0 · Grant/award (A): 250,000 (derivative) @ $0 · Option exercise (M): 233,334 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Clifton R. LaDuane | Option exercise (M): 140,667 @ $0 · Tax withholding (F): 48,513 @ $8.96 · Option exercise (M): 86,667 (derivative) @ $0 · Option exercise (M): 34,000 (derivative) @ $0 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | Secor Alicia — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-10-10 | 4 | McFarlane Neil F. — President and CEO, Director | Option exercise (M): 50,000 · Sale (S): 19,500 @ $10.82 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | FAVORITO TAMARA A — Director | Purchase (P): 3,175 @ $7.79 | EDGAR |
| 2025-09-15 | 4 | Shih Alvin — Director | Purchase (P): 20,000 @ $7.89 | EDGAR |
| 2025-08-20 | 4 | Bode John B — Director | Purchase (P): 5,000 @ $9.16 | EDGAR |
| 2025-06-30 | 4 | Thompson Rahsaan — Chief Legal & Compliance | Sale (S): 24,000 @ $9.21 | EDGAR |
| 2025-06-24 | 4 | Thompson Rahsaan — Chief Legal & Compliance | Option exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Shih Alvin — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Calder Douglas W — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Watton Corey Michael — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Bode John B — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Anderson Thomas — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | FAVORITO TAMARA A — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | DIXON WENDY L — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-03-31 | 4 | Watton Corey Michael — Director | Purchase (P): 300 @ $7.84 | EDGAR |
| 2025-03-27 | 4 | Quartel Adrian W — Chief Medical Officer | Grant/award (A): 68,000 (derivative) @ $0 · Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2025-03-21 | 4 | Bode John B — Director | Purchase (P): 10,000 @ $7.96 | EDGAR |
| 2025-02-14 | 4 | Sangiovanni Timothy J. — SVP, Finance & Corp Controller | Sale (S): 3,000 @ $7.86 | EDGAR |
| 2025-02-14 | 4 | Schafer Joshua — CCO & EVP, Bus. Development | Sale (S): 10,500 @ $7.86 | EDGAR |
| 2025-02-14 | 4 | Clifton R. LaDuane — CFO & Treasurer | Sale (S): 11,000 @ $7.86 | EDGAR |
| 2025-02-14 | 4 | McFarlane Neil F. — President and CEO, Director | Sale (S): 61,273 @ $7.86 · Sale (S): 30,544 @ $8.05 | EDGAR |
| 2025-02-10 | 4 | McFarlane Neil F. — President and CEO, Director | Grant/award (A): 225,000 (derivative) @ $0 · Grant/award (A): 112,500 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Sangiovanni Timothy J. — SVP, Finance & Corp Controller | Option exercise (M): 11,666 · Option exercise (M): 11,666 (derivative) @ $0 · Grant/award (A): 38,000 (derivative) @ $0 · Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Thompson Rahsaan — Chief Legal & Compliance | Grant/award (A): 68,000 (derivative) @ $0 · Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Schafer Joshua — CCO & EVP, Bus. Development | Option exercise (M): 35,333 · Option exercise (M): 35,333 (derivative) @ $0 · Grant/award (A): 68,000 (derivative) @ $0 · Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Clifton R. LaDuane — CFO & Treasurer | Option exercise (M): 43,333 · Option exercise (M): 43,333 (derivative) @ $0 · Grant/award (A): 68,000 (derivative) @ $0 · Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | McFarlane Neil F. — President and CEO, Director | Option exercise (M): 233,333 · Option exercise (M): 233,333 (derivative) @ $0 | EDGAR |
Recent 8-K events — ZEVRA THERAPEUTICS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ZVRA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →